173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors. (December 2022)

Record Type:: Journal Article
Title:: 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors. (December 2022)
Main Title:: 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors
Authors:: De Velasco Oria, G.A.
Garralda, E.
Moreno Garcia, V.
Melero, I.
Victoria Ruiz, I.
Indacochea, A.
Cervantes, A.
Oberoi, A.
Jones, D.
Lakins, M.A.
Kayitalire, L.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100285 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24685.xml